Bristol Myers (BMY) Q1 2026 Earnings Transcript

Bristol Myers Squibb reported Q1 revenue of $11.5 billion, up 1% year over year, with growth portfolio sales rising 9% to $6.2 billion and adjusted EPS of $1.58. Management reaffirmed full-year 2026 guidance and said results are tracking toward the upper end of its revenue and EPS ranges, while highlighting multiple pipeline catalysts including iberdomide PDUFA on August 17, positive mezigdomide Phase III interim data, and late-2026 readouts for milvexian and Cobenfy. The quarter also featured strong growth in Breyanzi (+53%), Reblozyl (+15%), Camzyos (+nearly 100%), and Eliquis (+13%), partly aided by inventory effects.

Analysis

BMY is transitioning from a single-asset patent cliff story into a barbell: mature cash engines still fund the dividend, while a growing share of value is now tied to multiple mid- to late-cycle assets. The key second-order implication is that investor focus should shift from headline revenue stability to mix durability—margin compression from newer launches is acceptable if it buys enough slope in the post-LOE growth curve to re-rate the multiple. That makes the stock less about near-term EPS optics and more about whether management can convert this year’s multiple catalysts into a credible 2027-2030 replacement cycle.

The market is likely underappreciating how much of the near-term setup is self-funded optionality. With ample cash and cost savings still coming, BMY can absorb pipeline spend and BD without depending on equity issuance or balance-sheet stress; that lowers the probability of a forced capital event if one of the late-year readouts disappoints. The flip side is that the stock now has several binary shots on goal clustered into the same 6-9 month window, which can cap multiple expansion until there is evidence the new franchises can offset any volatility in the legacy base.

The real asymmetric risk is not one trial fail, but correlation across readouts: if the cardiovascular, neuroscience, and fibrosis catalysts all land in a middling zone, the market may discount the entire pipeline as “good but not enough” and keep BMY in value-stock purgatory. Conversely, even one clearly differentiated data set with commercial clarity could re-anchor expectations for the portfolio and force longs to cover. The consensus still seems too anchored to legacy decay; what matters now is whether the growth portfolio can sustain high-single-digit growth while the company proves it can keep stacking new indications faster than the old franchises erode.

Key Decisions for Investors

• Initiate a tactical long BMY position into the next 6-9 months, but keep it sized as a catalyst basket rather than a core defensive pharma holding; the setup is attractive if even 1-2 of the late-year readouts are clean and commercially legible.
• Pair trade: long BMY / short a slower-growth large-cap pharma with higher dependence on a single franchise and fewer catalysts over the next 12 months; BMY has more embedded optionality and better self-funded BD capacity.
• Use call spreads instead of outright stock for the August-to-year-end window: upside is driven by discrete clinical/regulatory events, but the stock can still drift if data are merely acceptable rather than exceptional.
• If you already own BMY, hedge into the late-year catalyst cluster with short-dated puts or a collar; the risk is not fundamental collapse, but a multi-event disappointment that keeps the multiple compressed.
• Monitor for a post-readout add-on long if any one of the major programs delivers a clean de-risking event; the best risk/reward is likely after the first positive catalyst, not before it.